Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dimitrios Vassilopoulos

Showing results (141-150 of 169) with videos related to

Pageof 17
Sort By:
RMD Open|June 24, 2026
No benefit of adding glucocorticoids to maintenance treatment in reducing the risk of major relapses in ANCA-associated vasculitis: real life data from a longitudinal cohort studyKaterina Chavatza, Chrysoula G Gialouri, Konstantinos Drougkas, et al.
Rheumatology (Oxford, England)|May 25, 2023
Sustained cell-mediated but not humoral responses in rituximab-treated rheumatic patients after vaccination against SARS-CoV-2Κonstantinos Thomas, Ioannis Grigoropoulos, Panagiota Alexopoulou, et al.
Clinical and Experimental Rheumatology|December 2, 2014
Women's health and fertility, family planning and pregnancy in immune-mediated rheumatic diseases: a report from a south-eastern European Expert MeetingStella Ntali, Nemanja Damjanov, Peter Drakakis, et al.
Clinical and Experimental Rheumatology|July 8, 2016
Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a long-term, prospective real-life studyDimitrios Vassilopoulos, Evie M Delicha, Loukas Settas, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 9, 2026
Interstitial Lung Disease in ANCA-Associated Vasculitis: A European Multicentre StudyAglaia Chalkia, Marusa Kotnik, Timothy J Sadler, et al.
Clinical and Experimental Rheumatology|March 11, 2017
Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription databasePetros P Sfikakis, Vasiliki-Kalliopi Bournia, Prodromos Sidiropoulos, et al.
Rheumatology (Oxford, England)|June 30, 2020
Comparable or higher prevalence of comorbidities in antiphospholipid syndrome vs rheumatoid arthritis: a multicenter, case-control studyStylianos Panopoulos, Konstantinos Thomas, Georgios Georgiopoulos, et al.
Rheumatology International|February 1, 2024
Glucocorticoid discontinuation rate and risk factors for relapses in a contemporary cohort of patients with giant cell arteritisChristina Tsalapaki, Argyro Lazarini, Evaggelia Argyriou, et al.
Annals of the Rheumatic Diseases|August 14, 2020
2019 EULAR points to consider for the assessment of competences in rheumatology specialty trainingFrancisca Sivera, Alessia Alunno, Aurélie Najm, et al.
Rheumatology International|March 1, 2023
Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective studyPetros P Sfikakis, Dimitrios Vassilopoulos, Gkikas Katsifis, et al.
Pageof 17

Showing results (141-150 of 169) with videos related to

Sort By:
Pageof 17
RMD Open|June 24, 2026
No benefit of adding glucocorticoids to maintenance treatment in reducing the risk of major relapses in ANCA-associated vasculitis: real life data from a longitudinal cohort studyKaterina Chavatza, Chrysoula G Gialouri, Konstantinos Drougkas, et al.
Rheumatology (Oxford, England)|May 25, 2023
Sustained cell-mediated but not humoral responses in rituximab-treated rheumatic patients after vaccination against SARS-CoV-2Κonstantinos Thomas, Ioannis Grigoropoulos, Panagiota Alexopoulou, et al.
Clinical and Experimental Rheumatology|December 2, 2014
Women's health and fertility, family planning and pregnancy in immune-mediated rheumatic diseases: a report from a south-eastern European Expert MeetingStella Ntali, Nemanja Damjanov, Peter Drakakis, et al.
Clinical and Experimental Rheumatology|July 8, 2016
Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a long-term, prospective real-life studyDimitrios Vassilopoulos, Evie M Delicha, Loukas Settas, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 9, 2026
Interstitial Lung Disease in ANCA-Associated Vasculitis: A European Multicentre StudyAglaia Chalkia, Marusa Kotnik, Timothy J Sadler, et al.
Clinical and Experimental Rheumatology|March 11, 2017
Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription databasePetros P Sfikakis, Vasiliki-Kalliopi Bournia, Prodromos Sidiropoulos, et al.
Rheumatology (Oxford, England)|June 30, 2020
Comparable or higher prevalence of comorbidities in antiphospholipid syndrome vs rheumatoid arthritis: a multicenter, case-control studyStylianos Panopoulos, Konstantinos Thomas, Georgios Georgiopoulos, et al.
Rheumatology International|February 1, 2024
Glucocorticoid discontinuation rate and risk factors for relapses in a contemporary cohort of patients with giant cell arteritisChristina Tsalapaki, Argyro Lazarini, Evaggelia Argyriou, et al.
Annals of the Rheumatic Diseases|August 14, 2020
2019 EULAR points to consider for the assessment of competences in rheumatology specialty trainingFrancisca Sivera, Alessia Alunno, Aurélie Najm, et al.
Rheumatology International|March 1, 2023
Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective studyPetros P Sfikakis, Dimitrios Vassilopoulos, Gkikas Katsifis, et al.
Pageof 17